Skip to main content

Table 2 Candida species distribution and resistance to antifungal agents isolated from patients

From: The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study

Candida species

Elderly patients (≥65 years, n =63)

Younger patients (16-60 years, n =84)

Candida albicans

27/63 (42.9)

31/84 (36.9)

 Fluconazole

1/27 (3.7)

1/31 (3.2)

 Voriconazole

1/27 (3.7)

0/31 (0)

 Caspofungin

0/27 (0)

0/31 (0)

Non- C. albicans species

36/63 (57.1)

53/84 (63.1)

 Fluconazole

11/36 (30.6)

8/53 (15.1)

 Voriconazole

3/36 (8.3)

2/53 (3.8)

 Caspofungin

0/36 (0)

0/53 (0)

Candida tropicalis

16/63 (25.4)

19/84 (22.6)

 Fluconazole

4/16 (25.0)

1/19 (5.3)

 Voriconazole

2/16 (12.5)

1/19 (5.3)

 Caspofungin

0/16 (0)

0/19 (0)

Candida parapsilosis

9/63 (14.3)

17/84 (20.2)

 Fluconazole

2/9 (22.2)

1/17 (5.9)

 Voriconazole

0/9 (0.0)

0/17 (0)

 Caspofungin

0/9 (0)

0/17 (0)

Candida glabrata

7/63 (11.1)

9/84 (10.7)

 Fluconazole

2/7 (28.6)

0/9 (0)

 Voriconazole

1/7 (14.3)

0/9 (0)

 Caspofungin

0/7 (0)

0/9 (0)

Candida krusei a

3/63 (4.8)

6/84 (7.1)

 Fluconazole

3/3 (100.0)

6/6 (100.0)

 Voriconazole

0/3 (0)

1/6 (16.7%)

 Caspofungin

0/3 (0)

0/6 (0)

Othera

1/63 (1.6)*

2/84 (2.4) †

 Fluconazole

0/1 (0)

0/2 (0)

 Voriconazole

0/1 (0)

0/2 (0)

 Caspofungin

0/1 (0)

0/2 (0)

  1. Data are n (%).
  2. *including 1 C. famat.
  3. †including 1 C. rugosa and 1 C. guilliermondii.